Imprimis Pharmaceuticals Inc. (IMMY) Reaches New 1-Year Low at $3.50
Shares of Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) hit a new 52-week low on Thursday . The company traded as low as $3.50 and last traded at $3.51, with a volume of 27,437 shares changing hands. The stock had previously closed at $3.70.
Separately, Zacks Investment Research lowered shares of Imprimis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 20th.
The company has a 50 day moving average price of $3.87 and a 200-day moving average price of $4.40. The firm’s market capitalization is $46.70 million.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.16. The business had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.24 million. On average, equities research analysts forecast that Imprimis Pharmaceuticals Inc. will post ($0.94) earnings per share for the current fiscal year.
Imprimis Pharmaceuticals, Inc (Imprimis) is a pharmaceutical company. The Company focuses on developing and commercializing compounded drug therapies and making these therapies available to physicians and patients. It owns, markets and sells a portfolio of combination formulations in ophthalmology and urology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.